AHA · Chicago · 2026-11-06 – 2026-11-09
AHA Scientific Sessions 2026
1 de 21 ensayos Late-Breaking Science con resultadoLos resultados están embargados hasta cada presentación y aparecen aquí cuando se publican.
vie, 6 nov
sáb, 7 nov
LBS.01 The Dr. Eugene Braunwald Late-Breaking Science Session: Translating Science into Prevention: Lessons from Landmark Trials
08:35–09:50 (America/Chicago) · Center Stage, North Hall, Level 3- 08:35ZEUSEstudio clínicoPrimary Report of the Ziltivekimab Cardiovascular Outcomes Trial (ZEUS)Presentación sáb, 08:35
- 08:50Lp(a)HORIZON Estudio claveCardiología · Lípidos · Lipoproteína(a)En 8.323 pacientes con enfermedad cardiovascular establecida y Lp(a) ≥70 mg/dL, el pelacarsén 80 mg al mes no redujo el compuesto de muerte cardiovascular, infarto de miocardio, ictus o revascularización urgente en comparación con placebo.Leer →
- 09:00Lp(a)HORIZON extended analysesEstudio observacionalExtended Analyses of Cardiovascular Outcomes With Pelacarsen Treatment in the Lp(a)Horizon TrialPresentación sáb, 09:00
LBS.02 Late-breaking Science: Treating the Clot or Controlling the Blood Pressure: Improving Outcomes After Stroke
13:45–14:45 (America/Chicago) · Center Stage, North Hall, Level 3- 13:45OCEANIC-STROKE FraminghamEstudio observacionalOutcomes in the OCEANIC-STROKE Randomized, Placebo-Controlled Trial: FXIa Inhibition by Asundexian in Participants With Non-Cardioembolic Stroke or Transient Ischemic Attack by Non-Laboratory Framingham Risk Score CategoryPresentación sáb, 13:45
- 14:00REDUCEEstudio clínicoA Randomized Controlled Trial of Spironolactone-Based Blood Pressure Management After StrokePresentación sáb, 14:00
- 14:15OPTIMAL-StrokeEstudio clínicoIntensive Blood-Pressure Control for the Prevention of Major Cardiovascular Events in Patients With Prior Stroke: The OPTIMAL-Stroke TrialPresentación sáb, 14:15
LBS.03 Late-breaking Science: Hot Topics in CVD Prevention
15:15–16:30 (America/Chicago) · Center Stage, North Hall, Level 3- 15:15STREAMEstudio clínicoDiscontinuing Statins in Multimorbid Older Adults Without Cardiovascular Disease: A Randomized Non-Inferiority Clinical TrialPresentación sáb, 15:15
- 15:30OPTIMAL-DIABETESEstudio clínicoIntensive Blood Pressure Control for the Prevention of Major Cardiovascular Events in Patients With Type 2 Diabetes - The OPTIMAL-DIABETES TrialPresentación sáb, 15:30
- 15:45Ez-PAVEEstudio clínicoStatin-Ezetimibe Combination Therapy versus Statin Monotherapy in Patients With Atherosclerotic Cardiovascular Disease: Pre-Specified Second Randomization of the Ez-PAVE TrialPresentación sáb, 15:45
- 16:00Yoga-CaRe HFEstudio clínicoYoga-Based Cardiac Rehabilitation in Heart Failure With Reduced Ejection FractionPresentación sáb, 16:00
dom, 8 nov
LBS.04 Late-breaking Science: Innovations to Optimize Arrhythmia Care
15:30–16:45 (America/Chicago) · Center Stage, North Hall, Level 3- 15:30OptimPacingEstudio clínicoLeft Bundle Branch Pacing versus Right Ventricular Pacing for Atrioventricular Block: An International Multi-Center Randomized Controlled Trial (OptimPacing Study)Presentación dom, 15:30
- 15:45COAST-AFEstudio clínicoCharacterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation: COAST-AF Randomized TrialPresentación dom, 15:45
- 16:00SUPERIOREstudio clínicoSacubitril/Valsartan for Preventing Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Hypertension: A Multicenter, Randomized Controlled TrialPresentación dom, 16:00
- 16:15RACE-CARSEstudio clínicoRandomized Cluster Evaluation of Cardiac ARrest Systems (RACE-CARS) Trial Primary ResultsPresentación dom, 16:15
lun, 9 nov
LBS.05 Late-breaking Science: New Frontiers in Cardiometabolic Risk Reduction
08:00–09:15 (America/Chicago) · Center Stage, North Hall, Level 3- 08:00TYDAL-TIMI 78Estudio clínicoTYDAL-TIMI 78: A Randomized Trial of ANGPTL4 Inhibition With MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol ConcentrationsPresentación lun, 08:00
- 08:15CTX310Estudio clínicoCRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b TrialPresentación lun, 08:15
- 08:30ATTAIN-OSAEstudio clínicoOrforglipron for the Treatment of Obstructive Sleep Apnea: Results From Attain-OSAPresentación lun, 08:30
- 08:45SYNCHRONIZE-CVOTEstudio clínicoSurvodutide and Cardiovascular Outcomes in Obesity: Results from the SYNCHRONIZE®-CVOT TrialPresentación lun, 08:45
LBS.06 Late-breaking Science: Artificial Intelligence in the Diagnosis of Cardiovascular Disease
09:45–11:00 (America/Chicago) · Center Stage, North Hall, Level 3- 09:55WATCH-LVEstudio observacionalConsumer Smartwatch Artificial Intelligence-Enabled Electrocardiogram for Left Ventricular Systolic Dysfunction: Cross-Manufacturer Validation and Serial Home MonitoringPresentación lun, 09:55
- 10:05PROVAR+Estudio observacionalAI-Enabled Tele-ECG Identifies Structural Heart Disease and Prioritizes Echocardiography in Underserved Populations: The PROVAR+ External Validation StudyPresentación lun, 10:05
- 10:22AI echo interpretation RCTEstudio clínicoAI-Assisted Comprehensive Echocardiographic Interpretation—A Blinded, Randomized Controlled TrialPresentación lun, 10:22